By Mihir Mankad
Big pharma says high prices fund research and development, but costly drugs hit poor people hard and divert money needed to build clinics and pay nurses
Over the past year, high medicine prices have made the headlines. In the UK, two cancer treatments were dropped because they were deemed too expensive. A US Senate subcommittee criticised pharmaceutical company Gilead for charging $84,000 (£57,000) for a full course of its new hepatitis C treatments and found that fostering broad, affordable access for other drugs was not a major concern for the firm.
This is all without even mentioning the antics of everyone’s favourite villain, the pharmaceutical entrepreneur Martin Shkreli, who was called the most hated man in America for hiking the price of Daraprim, a malaria drug.
Read more here:: The Guardian – Global Development